Current Report Filing (8-k)
March 10 2020 - 4:31PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the Securities Exchange Act 1934
Date of
Report (Date of earliest event reported): March 10, 2020
NEMAURA
MEDICAL, INC.
(Exact name of
registrant as specified in charter)
Nevada
(State or other
jurisdiction of incorporation)
001-38355
|
|
46-5027260
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
|
|
57
West 57th Street
Manhattan,
NY
|
10019
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
|
|
Registrant’s
telephone number, including area code:
|
+1
(646) 416-8000
|
N/A
(Former
name or former address, if changed since last report)
|
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following
provisions:
[_] Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant
to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
[_] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
Common
Stock
|
NMRD
|
The
Nasdaq Stock Market LLC
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01.
Regulation FD Disclosure.
Nemaura Medical,
Inc., a Nevada corporation (the “Company”) issued a press release (the “Press Release”) on March 10, 2020.
A copy of the Press Release is attached as Exhibit 99.1 hereto. The information included in the Press Release shall not be deemed
to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such a filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated: March 10, 2020
|
Nemaura Medical, Inc.
|
|
|
|
By:
|
/s/ Dewan F. H. Chowdhury
|
|
Name:
Title:
|
Dewan F. H. Chowdhury
Chief Executive Officer
|
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Sep 2023 to Sep 2024